|By PR Newswire||
|March 14, 2014 08:00 AM EDT||
NEW YORK, March 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Stryker Corporation (NYSE: SYK), ArthroCare Corporation (NASDAQ: ARTC), Novavax, Inc. (NASDAQ: NVAX), The Cooper Companies, Inc. (NYSE: COO), and Varian Medical Systems, Inc. (NYSE: VAR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Stryker Corporation Analyst Notes
On March 7, 2014, Stryker Corporation (Stryker) reported that it has completed the previously announced acquisition of Pivot Medical Inc. According to Stryker, as indicated previously on February 19, 2014, the transaction is expected to be neutral to its 2014 earnings per share excluding acquisition, integration-related and intangible amortization charges. The full analyst notes on Stryker Corporation are available to download free of charge at:
ArthroCare Corporation Analyst Notes
On March 11, 2014, shares of ArthroCare Corporation (ArthroCare) increased 0.02% to close at $48.18. ArthroCare's shares dropped slightly 0.15% over the previous three trading sessions, while the Nasdaq Composite Index dipped 1.03% during the same period. The full analyst notes on ArthroCare Corporation are available to download free of charge at:
Novavax, Inc. Analyst Notes
On March 10, 2014, Novavax, Inc. (Novavax) announced that it has appointed John J. Trizzino as Senior Vice President, Commercial Operations, effective immediately. According to the Company, Trizzino will be responsible for developing and implementing the commercialization strategy in support of the Company's product candidates, including its RSV F, quadrivalent seasonal and pandemic influenza vaccine candidates. Prior to his appointment, Trizzino served as Novavax' Senior Vice President of International and Government Alliances, beginning in 2009 and its Senior Vice President of Business Development from 2010 to 2011. Stan Erck, President and CEO of Novavax, said, "With our success in product development in the clinic, and our expectations around future development plans, we recognize the need to maximize the value of our vaccine candidates through a fully developed commercialization strategy. John's knowledge of the vaccine industry, with specific experience in vaccine commercialization, distribution and reimbursement, provide us with the insight needed to develop that commercialization strategy. We are very excited to have John return to the team and look forward to his contributions to our success." The full analyst notes on Novavax, Inc. are available to download free of charge at:
The Cooper Companies, Inc. Analyst Notes
On March 6, 2014, The Cooper Companies, Inc. (Cooper) released its Q1 FY 2014 financial results (period ended January 31, 2014). For the quarter, Cooper reported a 6.6% YoY rise in net sales of $405.0 million. Q1 FY 2014 net income attributable to Cooper's stockholders stood at $71.8 million or $1.47 per diluted share, compared with $74.7 million or $1.50 per diluted share in Q1 FY 2013. "We are very pleased to report a strong first quarter. CooperVision continued to gain share in all geographies and modalities with silicone hydrogel products showing especially strong growth led by Biofinity®. CooperSurgical also continued to post solid revenue growth in fertility. Our businesses continue to perform well and we remain excited about the future," commented Robert S. Weiss, Cooper's President and CEO. The full analyst notes on The Cooper Companies, Inc. are available to download free of charge at:
Varian Medical Systems, Inc. Analyst Notes
On March 11, 2014, Varian Medical Systems, Inc. (Varian) reported that Meridian Health of New Jersey has initiated a program to deploy TrueBeam™ technology from the Company across its network of cancer treatment clinics. The Company stated that Meridian plans to install seven TrueBeam machines at its five sites, together with Varian's ARIA® data management and Eclipse™ treatment planning software. The network will be integrated and centrally managed using Varian's FullScale™ cloud-based oncology IT data hosting solution. Commenting on the development, Mark J. Krasna, M.D., Corporate Medical Director for Meridian Cancer Care, said, "These new technologies will support our multi-disciplinary team of experts us as we continue to expand our state of the art radiation therapy program at Meridian. The TrueBeam machines help enhance our radiosurgery capabilities to patients throughout central and southern New Jersey, offer many patients shorter treatments, and add arc therapy to the range of treatment options we currently utilize." The full analyst notes on Varian Medical Systems, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review